You won't get any argument from me that hitting VEGFR is a concern. However, I'm betting that Iclusig's overall safety profile is in the same ballpark as existing tki's. If it is, and Iclusig delivers a significantly better MMR when compared to sprycel/tasigna (say 55% vs 45%),then the market is significantly underestimating the 1L/2L commercial opportunity. Hopefully MDA's ASH data will provide additional clarity...buckle up!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.